Predicting therapeutic response to neoadjuvant immunotherapy based on an integration model in resectable stage IIIA (N2) non-small cell lung cancer.
Xu L, Si H, Zhuang F, Li C, Zhang L, Zhao Y, Chen T, Dong Y, Wang T, Hou L, Hu T, Sun T, She Y, Hu X, Xie D, Wu J, Wu C, Zhao D, Chen C.
Xu L, et al. Among authors: hu t.
J Thorac Cardiovasc Surg. 2024 May 17:S0022-5223(24)00437-9. doi: 10.1016/j.jtcvs.2024.05.006. Online ahead of print.
J Thorac Cardiovasc Surg. 2024.
PMID: 38763304